Central NSCLC: SBRT yields good outcomes in meta-analysis

  • Clin Lung Cancer

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Stereotactic body radiotherapy (SBRT) at a biologically equivalent dose (BED10Gy) ≥100 Gy offered better rates of local control (LC) and OS than (BED10Gy)

Why this matters

  • Prior studies yielded conflicting results about the benefit of SBRT in centrally located NSCLC.

Study design

  • Meta-analysis of 13 studies with 599 patients with centrally located NSCLC who received SBRT.
  • Funding: National Research Fund of Korea.

Key results

  • Pooled 1-, 2-, and 3-year OS was 86.1%, 64.0%, and 50.5%, respectively.
  • Pooled 1-, 2-, and 3-year LC was 91.3%, 82.2%, and 72.2%, respectively.
  • Pooled grade ≥3 complication rate was 9.1%.
  • BED10Gy ≥100 Gy was associated with better OS at 1, 2, and 3 years than BED10Gy
  • ≥100 Gy: 88.4%, 66.9%, and 53.0%, respectively.
  • BED10Gy ≥100 Gy was associated with better LC at 1, 2, and 3 years than BED10Gy
  • ≥100 Gy: 93.6%, 86.7%, and 77.6%, respectively.
  • Limitations

    • Analysis included only observational studies.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit